Navigation Links
Excellence in High Intensity Focused Ultrasound (HIFU) Outcomes

SARASOTA, Fla., Nov. 12, 2013 /PRNewswire/ --  Introduction – Currently more than 240,000 men are diagnosed yearly with prostate cancer while it is projected through SEER data that 500,000 men will be diagnosed within approximately 5 years. Additionally, prostate cancer is the most dominant (non-cutaneous) cancer diagnosed in men.

Since 2006 two specific HIFU treatment centers have provided procedures for organ confined prostate cancer in North America.  The treating centers are Maple Leaf HIFU, represented by William L. Orovan, M.D. (Toronto, Canada) while PanAm HIFU™ has been represented by Ronald E. Wheeler, M.D., of Sarasota, Florida; treating in Cancun, Mexico and London, England.  Heretofore, there has been no comparison of North American HIFU treatment outcome data.

Dr. Orovan's data comes exclusively from Ablatherm™ technology while Dr. Wheeler's work comes from the Ablatherm™ technology as well as the Sonablate 500™ technology. This comparison is warranted based on the public perception that all institutions are equal regarding outcome data when HIFU is performed. The following data will demonstrate that the treatment outcome data from PanAm HIFU™ is superior to that performed by Maple Leaf HIFU. Because many men may choose HIFU based on location or price point alone, this report gives reason to reconsider where they treat for HIFU and with whom they treat.

Methods –Dr. Orovan's outcome data can be found in the British Journal of Urology, International Edition published in 2012. His research article is entitled, "Single-session primary high intensity focused ultrasonography treatment for localized prostate cancer: biochemical outcomes using third generation-based technology". In total, Dr. Orovan reported on 402 patients treated between 2005 and 2010. 100% of Dr. Orovan's patients received biopsy confirmation while no patients were identified as having had an MRI (Magnetic Resonance Imaging) scan prior to the HIFU procedure.  Dr. Wheeler's outcome data is noted in a study of 147 patients who qualified by virtue of preselected study criteria associated with a PSA value of ≤ 8.5 ng/ml, a Gleason Score of ≤ 8 (4+4) with subsequent treatment within 4 years of diagnosis. All patients in Dr. Wheeler's research had been diagnosed with either a biopsy or an MRI scan or both. Specifically, 70 patients had a confirmational biopsy (either proceeded by a scan or followed by a scan), while 77 patients were diagnosed by MRI (+ or – Spectroscopy) alone.

Results – Dr. Orovan qualified his group in accordance with the D'Amico stratification criteria as low and intermediate risk. Of 402 patients treated and followed to 4 years, 183 (45.5%) were low risk and 219 (54.5%) were intermediate risk. For clarity purpose, a low grade cancer in Dr. Orovan's treatment group was a Gleason score 6 (3+3) while the intermediate group comprised a Gleason score 7 (3+4, 4+3). Depending on which classification for success was utilized Dr. Orovan's data reflected a cure rate of 76% for the Gleason 6 cancers while his cure rate was 69.5% for the Gleason grades of 7 (3+4, 4+3). Cure was defined by biochemical stability of the nadir (= .36 ng/ml) reached while failure was defined when a PSA value that reached the nadir and then rose to some point consistent with failure as defined by the Stuttgart or Horowitz definition. In Dr. Wheeler's data 147 patients received HIFU and followed for up to 6 years. In his data using a nadir (˂ .30 ng/ml) all but one patient succeeded with a cure rate of 99%. Specifically, the biopsy group (N= 70) noted the following characteristics: 37 patients had a Gleason score of 6, while 31 patients had an intermediate cancer of 7 (3+4, 4+3) and 2 patients had a very aggressive cancer of 8 (4+4). The men diagnosed with a MRI scan alone (N= 77) did as well as the biopsy group with a 99% cure.

Conclusion –It is clear that treatment outcome data varied significantly and must be understood by the patient when prostate cancer is diagnosed. It is quite possible that the MRI findings used by Dr. Wheeler gave him an additional diagnostic component or possible that individual treating physicians have treatment characteristics or qualities unique to themselves, allowing one to succeed more often while another may fail. Without question no matter the reason for success, Dr. Orovan had a success rate that must be improved upon if Maple Leaf HIFU™ expects to compete within the US population of organ confined prostate cancer patients. Patients will not accept failure when success has been defined as definitely and conclusively as this comparison represents. At this point in time, it is clear that location and cost should not be the controlling factor in deciding where patients are treated for prostate cancer.  Patients interested in knowing more about PanAm HIFU™, and the diagnostic protocol developed by Dr. Wheeler, are encouraged to view their website: or visit with our staff by calling: Dr. Ronald Wheeler at 941-957-0007.

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. UBM Canon and MD+DI Proudly Announce 25 Innovative Products as Winners of the 2012 Medical Design Excellence Awards
2. Premier healthcare alliance honors Atrium Medical Corporation for operational excellence
3. Call for Entries: International Bureau for Epilepsy and UCB launch the 2012 Excellence in Epilepsy Journalism Award to recognize exceptional reporting on epilepsy
4. Upsher-Smith Is Honored with Prestigious Industry Award for Excellence and Innovation
5. Physicians Practice Recognized for Print and Digital Excellence
6. UBM Canon, the Global MedTech Authority, and the Medical Design Excellence Awards Honored Dr. Thomas Fogarty with the 2012 Lifetime Achievement Award
7. Transonic Systems Selects Infinity Info Systems To Implement Microsoft Dynamics CRM To Drive Business Performance And Operational Excellence
8. Spot Vision Screener wins Bronze in International Design Excellence Awards
9. Fourth Annual Spine Technology Awards to Recognize Excellence and Innovation
10. CPhI Japan Triumphs in the Prestigious AEO Excellence Awards
11. Somnetics Pioneering CPAP Device Receives the 2012 North American Frost & Sullivan Award for Product Differentiation Excellence
Post Your Comments:
(Date:11/24/2015)... Nueva York , 24 de noviembre de ... del Avery Breathing Pacemaker System, se complace anunciar ... Ph.D. como consultor clínico. ... Foto -   ... Jonzon es un fisiólogo y consultor en neonatología ...
(Date:11/24/2015)... 2015 --> --> ... Market by Product Type (Bone Graft, Bine Graft Substitute, Platelet ... Posterior Lumbar Interbody Fusion), End User, and Geography - Global ... valued at $1.90 Billion in 2014 and is expected to ... during the forecast period of 2015 to 2020. ...
(Date:11/24/2015)... FRAMINGHAM, Mass. , Nov. 24, 2015   ... leading innovator of less-invasive, miniaturized circulatory support technologies that ... announced that President and Chief Executive Officer Doug ... Jaffray 27 th Annual Healthcare Conference on December ... being held December 1-2 in New York ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, officials ... the Narconon network, announced the release of a new cutting edge recovery program that ... has been working with drug- and alcohol-addicted individuals with the purpose to free addicts ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Smiles by ... TMJ Disorder, Bruxism, and moderate facial wrinkling. While many patients are aware of the ... the great success Botox® delivers to those suffering with discomfort, soreness, and pain as ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted ... in Chicago, IL, UV Angel is evaluating the efficacy of its product and its ... units (totaling 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, ...
(Date:11/25/2015)... ... 25, 2015 , ... In honor of Pulmonary Hypertension Awareness ... groups responsible for advancing care for pulmonary hypertension (PH) patients and helping to ... will receive special recognition throughout 2016 as part of PHA’s 25th anniversary celebrations. ...
(Date:11/25/2015)... MA (PRWEB) , ... November 25, 2015 , ... Many ... — fatigue, fuzzy-headedness, weight gain, cold hands, and dry skin. But many people who ... their diet and exercise regimen instead of their thyroid, especially if they don’t have ...
Breaking Medicine News(10 mins):